These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33478201)

  • 1. Expressions of ZNF436, β-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances.
    Chen Z; Cui N; Zhao JS; Wu JF; Ma F; Li C; Liu XY
    Eur J Histochem; 2021 Jan; 65(1):. PubMed ID: 33478201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression and significance of CMTM5 and epidermal growth factor receptor in prostate cancer].
    Yuan YQ; Zhang YX; Liu ZH; Qin CP; Sheng ZZ; Xu T; Wang XF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Aug; 47(4):571-6. PubMed ID: 26284387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway.
    Li L; Hu Y; Chen D; Zhu J; Bao W; Xu X; Chen H; Chen W; Feng R
    Mol Med Rep; 2022 Jan; 25(1):. PubMed ID: 34791506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer.
    Xu C; Liu F; Xiang G; Cao L; Wang S; Liu J; Meng Q; Xu D; Lv S; Jiao J; Niu Y
    J Exp Clin Cancer Res; 2019 Jun; 38(1):238. PubMed ID: 31171012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced CMTM5 expression correlates with carcinogenesis in human epithelial ovarian cancer.
    Li P; Liu K; Li L; Yang M; Gao W; Feng J; Lv Y; Qu X; Kong B
    Int J Gynecol Cancer; 2011 Oct; 21(7):1248-55. PubMed ID: 21841490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CMTM5 exhibits tumor suppressor activity through promoter methylation in oral squamous cell carcinoma.
    Zhang H; Nan X; Li X; Chen Y; Zhang J; Sun L; Han W; Li T
    Biochem Biophys Res Commun; 2014 May; 447(2):304-10. PubMed ID: 24721428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Research advances in CKLF-like MARVEL transmembrane domain containing member 5].
    Yuan YQ; Xiao YB; Liu ZH; Zhang XW; Xu T; Wang XF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2012 Dec; 34(6):625-8. PubMed ID: 23286412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CMTM5 inhibits the tumor cell behavior of prostate cancer by downregulation of HER2].
    Xu T; Li J; Xiao YB; Liu ZH; Li Q; Wang XF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2010 Aug; 42(4):386-90. PubMed ID: 20721248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Abnormally lower expression of cmtm5 gene in bone marrow cells from patients with multiple myeloma].
    Niu JH; Bao L; Zhang Y; Li JL; Li LD; Xie M; Qin YZ; Lai YY; Jiang Q; Shi HL; Liu YR; Jiang B; Chen SS; Huang XJ; Ruan GR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):363-7. PubMed ID: 20416169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
    Išić Denčić T; Bartolome A; Šelemetjev S; Đorić I; Tatić S; Živaljević V; Cvejić D
    Exp Mol Pathol; 2018 Oct; 105(2):181-189. PubMed ID: 30077672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-regulation of miR-10b-3p promotes the progression of hepatocellular carcinoma cells via targeting CMTM5.
    Guan L; Ji D; Liang N; Li S; Sun B
    J Cell Mol Med; 2018 Jul; 22(7):3434-3441. PubMed ID: 29691981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo.
    Xiao Y; Yuan Y; Zhang Y; Li J; Liu Z; Zhang X; Sheng Z; Xu T; Wang X
    Clin Transl Oncol; 2015 Jun; 17(6):431-7. PubMed ID: 25387568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of polyethylenimine-functionalized gold nanoclusters carrying plasmid CMTM5 in impeding the malignant progression of prostate cancer cells by promoting EGFR endocytosis.
    Li L; Li C; Miao F; Chen W; Kong X; Ye R; Feng R
    Neoplasma; 2024 Feb; 71(1):48-59. PubMed ID: 38295104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CMTM5/7 are biomarkers and prognostic factors in human breast carcinoma.
    Wu J
    Cancer Biomark; 2020; 29(1):89-99. PubMed ID: 32568178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative immunohistochemical expression of β-catenin, EGFR, ErbB2, and p63 in adamantinomatous and papillary craniopharyngiomas.
    Esheba GE; Hassan AA
    J Egypt Natl Canc Inst; 2015 Sep; 27(3):139-45. PubMed ID: 26198262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent inactivation of MCC/CTNNBIP1 and overexpression of phospho-beta-catenin(Y654) are associated with breast carcinoma: Clinical and prognostic significance.
    Mukherjee N; Dasgupta H; Bhattacharya R; Pal D; Roy R; Islam S; Alam N; Biswas J; Roy A; Roychoudhury S; Panda CK
    Biochim Biophys Acta; 2016 Sep; 1862(9):1472-84. PubMed ID: 27208794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inhibitory effect of CMTM5 on xenografted human prostatic cancer in nude mice].
    Xiao YB; Xie J; Zhang GX; Li J; Hao YC; Zhang XW; Liu ZH; Xu T; Wang XF
    Zhonghua Nan Ke Xue; 2012 Mar; 18(3):195-9. PubMed ID: 22474980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of aspirin response-related transcripts in patients with coronary artery disease and preliminary investigation on CMTM5 function.
    Zhang JW; Liu TF; Chen XH; Liang WY; Feng XR; Wang L; Fu SW; McCaffrey TA; Liu ML
    Gene; 2017 Aug; 624():56-65. PubMed ID: 28457985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Akt1 inhibition promotes breast cancer metastasis through EGFR-mediated β-catenin nuclear accumulation.
    Li W; Hou JZ; Niu J; Xi ZQ; Ma C; Sun H; Wang CJ; Fang D; Li Q; Xie SQ
    Cell Commun Signal; 2018 Nov; 16(1):82. PubMed ID: 30445978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of cyclin D1, β-catenin, and MTA1 in patients with invasive ductal carcinoma of the breast.
    Cheng CW; Liu YF; Yu JC; Wang HW; Ding SL; Hsiung CN; Hsu HM; Shieh JC; Wu PE; Shen CY
    Ann Surg Oncol; 2012 Dec; 19(13):4129-39. PubMed ID: 22864797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.